Profile data is unavailable for this security.
About the company
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
- Revenue in USD (TTM)225.21m
- Net income in USD-15.70m
- Incorporated1977
- Employees622.00
- LocationAxoGen Inc13631 Progress Blvd., Suite 400ALACHUA 32615United StatesUSA
- Phone+1 (386) 462-6817
- Fax+1 (386) 462-6801
- Websitehttps://www.axogeninc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pulse Biosciences Inc | 350.00k | -72.78m | 1.28bn | 116.00 | -- | 15.85 | -- | 3,661.70 | -1.08 | -1.08 | 0.0052 | 1.19 | 0.0031 | -- | -- | 3,017.24 | -64.12 | -74.23 | -69.64 | -82.45 | -54.00 | -- | -20,794.57 | -11,780.43 | 10.51 | -- | 0.00 | -- | -- | -- | -35.82 | -- | -5.35 | -- |
| Adapthealth Corp | 3.24bn | -70.27m | 1.31bn | 10.90k | -- | 0.8599 | 3.96 | 0.4038 | -0.5224 | -0.5224 | 23.84 | 11.21 | 0.7372 | 17.60 | 8.33 | 297,693.30 | -1.50 | -1.84 | -1.76 | -2.08 | 21.07 | 20.27 | -2.04 | -2.74 | 0.8109 | 1.96 | 0.5393 | -- | -0.4943 | 25.16 | -185.55 | -- | 57.26 | -- |
| Iradimed Corp | 83.81m | 22.48m | 1.32bn | 160.00 | 59.30 | 13.95 | 78.44 | 15.75 | 1.75 | 1.75 | 6.52 | 7.44 | 0.8094 | -- | -- | -- | 21.71 | 18.06 | 23.86 | 20.21 | 76.75 | 76.85 | 26.82 | 25.51 | -- | -- | -- | -- | 14.43 | 21.45 | 16.88 | 108.61 | -- | -- |
| Kestra Medical Technologies Ltd | 74.26m | -138.79m | 1.33bn | 330.00 | -- | 7.13 | -- | 17.88 | -2.76 | -2.76 | 1.47 | 3.19 | 0.4034 | -- | 9.40 | 225,027.30 | -71.43 | -122.23 | -92.37 | -192.35 | 46.40 | -- | -177.06 | -342.51 | -- | -116.72 | 0.2033 | -- | 115.05 | -- | -25.08 | -- | 150.61 | -- |
| Conmed Corp | 1.37bn | 47.06m | 1.41bn | 3.90k | 30.27 | 1.37 | 11.64 | 1.03 | 1.51 | 1.51 | 44.20 | 33.36 | 0.5936 | 1.78 | 5.66 | 352,493.60 | 2.03 | 2.11 | 2.33 | 2.41 | 54.59 | 54.98 | 3.42 | 3.78 | 1.01 | 3.30 | 0.447 | 51.06 | 5.18 | 9.77 | -64.47 | 37.66 | 8.76 | -5.59 |
| Procept Biorobotics Corp | 308.05m | -95.57m | 1.46bn | 888.00 | -- | 3.99 | -- | 4.74 | -1.72 | -1.72 | 5.55 | 6.50 | 0.5912 | 1.76 | 3.69 | 346,907.70 | -18.34 | -23.13 | -20.70 | -25.70 | 63.70 | 58.76 | -31.02 | -56.52 | 5.77 | -- | 0.1236 | -- | 37.22 | 109.04 | -4.55 | -- | 109.29 | -- |
| Enovis Corp | 2.25bn | -1.18bn | 1.47bn | 7.80k | -- | 0.9868 | -- | 0.6544 | -20.69 | -20.72 | 39.39 | 26.05 | 0.5256 | 1.66 | 5.29 | 288,137.50 | -27.63 | -7.98 | -31.84 | -9.05 | 58.16 | 56.87 | -52.57 | -24.34 | 1.04 | 1.06 | 0.465 | -- | 6.66 | -6.05 | -42.80 | -- | 11.45 | -- |
| Novocure Ltd | 655.35m | -136.23m | 1.54bn | 1.61k | -- | 4.47 | -- | 2.35 | -1.22 | -1.22 | 5.88 | 3.03 | 0.6409 | 4.35 | 8.01 | 408,319.60 | -13.32 | -11.74 | -25.57 | -15.63 | 74.73 | 76.71 | -20.79 | -23.31 | 2.71 | -- | 0.3642 | -- | 8.28 | 5.80 | 19.21 | -- | 12.23 | -- |
| Quidelortho Corp | 2.73bn | -1.13bn | 1.54bn | 6.50k | -- | 0.799 | -- | 0.5636 | -16.66 | -16.66 | 40.25 | 28.28 | 0.4478 | 2.62 | 7.12 | 420,030.80 | -18.56 | -6.45 | -22.13 | -7.39 | 46.67 | 53.89 | -41.45 | -14.40 | 0.9002 | 0.3677 | 0.5798 | -- | -1.89 | 10.44 | 44.84 | -- | 23.72 | -- |
| AtriCure Inc | 534.53m | -11.45m | 1.54bn | 1.35k | -- | 3.13 | 169.62 | 2.88 | -0.241 | -0.241 | 11.19 | 9.88 | 0.8461 | 1.74 | 8.42 | 395,946.70 | -1.81 | -2.67 | -2.07 | -2.98 | 74.98 | 74.88 | -2.14 | -4.13 | 2.99 | -6.75 | 0.1232 | -- | 14.88 | 20.95 | 74.39 | -- | 23.40 | -- |
| UFP Technologies Inc | 602.80m | 68.31m | 1.58bn | 4.15k | 23.28 | 3.72 | 18.02 | 2.61 | 8.78 | 8.78 | 77.44 | 54.96 | 0.9389 | 4.96 | 7.19 | -- | 10.64 | 10.57 | 12.06 | 12.07 | 28.27 | 27.60 | 11.33 | 11.12 | 1.52 | 9.46 | 0.2422 | -- | 19.50 | 27.43 | 15.82 | 38.57 | -- | -- |
| AxoGen Inc | 225.21m | -15.70m | 1.59bn | 622.00 | -- | 11.23 | -- | 7.06 | -0.3413 | -0.3413 | 4.77 | 2.73 | 1.06 | 1.53 | 8.96 | 362,070.80 | -7.38 | -10.17 | -8.46 | -11.70 | 74.31 | 77.27 | -6.97 | -12.34 | 3.31 | -0.9786 | 0.2732 | -- | 20.21 | 14.93 | -57.60 | -- | -24.36 | -- |
| Tandem Diabetes Care Inc | 1.01bn | -204.71m | 1.72bn | 2.50k | -- | 11.10 | -- | 1.70 | -3.07 | -3.07 | 15.08 | 2.27 | 1.10 | 3.37 | 7.25 | 405,894.40 | -22.15 | -12.88 | -30.13 | -16.00 | 53.81 | 52.12 | -20.17 | -14.32 | 2.02 | -6.00 | 0.6699 | -- | 7.93 | 15.26 | -113.18 | -- | -9.19 | -- |
| Artivion Inc | 441.33m | 9.76m | 1.85bn | 1.80k | 194.04 | 4.11 | 57.28 | 4.18 | 0.1987 | 0.1987 | 9.44 | 9.37 | 0.5273 | 1.82 | 5.22 | 245,183.30 | 1.17 | -1.72 | 1.30 | -1.86 | 64.40 | 64.69 | 2.21 | -3.80 | 2.62 | 1.44 | 0.3278 | -- | 13.59 | 11.75 | 173.17 | -- | 39.74 | -- |
| Inspire Medical Systems Inc | 911.98m | 145.42m | 1.85bn | 1.33k | 13.04 | 2.37 | 11.62 | 2.03 | 4.97 | 4.97 | 30.75 | 27.33 | 1.06 | 1.18 | 8.57 | 684,156.80 | 16.95 | 3.09 | 19.00 | 3.48 | 85.39 | 84.83 | 15.95 | 3.05 | 4.56 | -- | 0.00 | 0.00 | 13.60 | 51.21 | 171.77 | -- | 73.41 | -- |
| Omnicell Inc | 1.18bn | 2.05m | 1.87bn | 3.58k | 954.42 | 1.51 | 22.89 | 1.58 | 0.0432 | 0.0432 | 25.70 | 27.36 | 0.5786 | 7.19 | 5.01 | 330,962.30 | 0.1002 | 0.7331 | 0.1357 | 0.9767 | 42.49 | 44.88 | 0.1732 | 1.32 | 1.22 | -- | 0.1198 | 0.00 | 6.53 | 5.84 | -83.62 | -42.34 | 1.93 | -- |
Data as of Mar 02 2026. Currency figures normalised to AxoGen Inc's reporting currency: US Dollar USD
41.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| First Light Asset Management LLCas of 31 Dec 2025 | 5.23m | 10.44% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.27m | 6.53% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.49m | 4.97% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 2.43m | 4.84% |
| ArrowMark Colorado Holdings LLCas of 31 Dec 2025 | 1.47m | 2.94% |
| Assenagon Asset Management SA (Germany)as of 31 Dec 2025 | 1.38m | 2.75% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2025 | 1.21m | 2.41% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.10m | 2.19% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.08m | 2.15% |
| Millennium Management LLCas of 31 Dec 2025 | 971.36k | 1.94% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
